89Bio Inc (NASDAQ:ETNB)

25.60
Delayed Data
As of Sep 25
 +1.18 / +4.83%
Today’s Change
14.00
Today|||52-Week Range
47.25
-2.62%
Year-to-Date
Wall Street Breakfast: What Moved Markets
Sep 19 / Seeking Alpha - Paid Partner Content
Marinus Pharmaceuticals, Plus Therapeutics among healthcare gainers, Nano-X Imaging, Vaxart leads losers
Sep 15 / Seeking Alpha - Paid Partner Content
MRSN, FSLR among premarket losers
Sep 17 / Seeking Alpha - Paid Partner Content
Marinus Pharmaceuticals, Plus Therapeutics among healthcare gainers, Nano-X Imaging, Vaxart lead losers
Sep 15 / Seeking Alpha - Paid Partner Content
89bio prices upsized equity offering at $28
Sep 17 / Seeking Alpha - Paid Partner Content
89Bio readies public offering
Sep 14 / Seeking Alpha - Paid Partner Content
INO, ARWR, ADT and AXL among midday movers
Sep 16 / Seeking Alpha - Paid Partner Content
89bio's lead drug shows positive effect in NASH study
Sep 14 / Seeking Alpha - Paid Partner Content
OCN, PSTV, VXRT and SAVA among midday movers
Sep 15 / Seeking Alpha - Paid Partner Content
IPO Update: Metacrine Seeks $85 Million U.S. IPO
Sep 11 / Seeking Alpha - Paid Partner Content

Today’s Trading

Previous close24.42
Today’s open25.16
Day’s range24.71 - 25.98
Volume12,144
Average volume (3 months)134,082
Market cap$503.3M
Data as of 3:59pm ET, 09/25/2020

Growth & Valuation

Earnings growth (last year)-1,988.02%
Earnings growth (this year)+87.23%
Earnings growth (next 5 years)+15.97%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book3.88

Competitors

No competitors data available.

Financials

Next reporting dateDecember 16, 2020
EPS forecast (this quarter)-$0.87
Annual revenue (last year)$0.00
Annual profit (last year)-$57.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
--, --

Forecasts